Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Medtronic
Johnson and Johnson
Boehringer Ingelheim
Dow

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,409,616

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,409,616 protect, and when does it expire?

Patent 8,409,616 protects OXAYDO and is included in one NDA.

This patent has thirteen patent family members in six countries.

Summary for Patent: 8,409,616
Title:Extended release opioid abuse deterrent compositions and methods of making same
Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
Inventor(s): Kumar; Vijai (Morris Plains, NJ), Dixon; David (Woodside, NY), Tewari; Divya (Suffern, NY), Wadgaonkar; Dilip B. (Suffern, NY)
Assignee: Acura Pharmaceuticals, Inc. (Palatine, IL)
Application Number:13/327,252
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,409,616
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 8,409,616

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Zyla OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-001 Jun 17, 2011 RX No No   Start Trial   Start Trial Y   Start Trial
Zyla OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-002 Jun 17, 2011 RX No No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,409,616

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004294953   Start Trial
Australia 2010200979   Start Trial
Australia 2013206525   Start Trial
Australia 2015264950   Start Trial
Australia 2017239544   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Mallinckrodt
Harvard Business School
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.